| By PR Newswire | Article Rating: |
|
| October 15, 2012 10:13 AM EDT |
WHITE PLAINS, N.Y., Oct. 15, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was saddened to learn of the death of Senator Arlen Specter from complications related to non-Hodgkin lymphoma.
Specter, Senator from Pennsylvania from 1980 until 2010, had previously fought Hodgkin's disease in 2005, and later survived a brain tumor and heart bypass surgery.
Specter was an ardent advocate for medical research, continually pushing for more funding for the National Institutes of Health budget.
"Our thoughts are with Senator Specter's family," said LLS President and CEO John Walter. "LLS is relentless in its pursuit of new therapies to defeat these diseases."
In light of his death, LLS is available to provide background on both Hodgkin and non-Hodgkin lymphoma. To arrange interviews please contact Andrea Greif, 914-821-8958 or andrea.greif@lls.org.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.
Andrea Greif
W: (914)821-8958
C: (914)772-3027
andrea.greif@lls.org
SOURCE The Leukemia & Lymphoma Society
Published October 15, 2012
Copyright © 2012 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

